Literature DB >> 10360648

Caspase-3 activation during apoptosis caused by glutathione-doxorubicin conjugate.

T Asakura1, T Sawai, Y Hashidume, Y Ohkawa, S Yokoyama, K Ohkawa.   

Abstract

Glutathione-doxorubicin (GSH-DXR) effectively induced apoptosis in rat hepatoma cells (AH66) at a lower concentration than DXR. After 24 h of drug treatment, DNA fragmentation of the cells was observed at the concentration of 1.0 microM DXR or 0.01 microM GSH-DXR. Increase in caspase-3 activity and DNA fragmentation were observed within 12 h and 15 h after treatment with either drug. Intracellular caspase-3 activity was increased in a dose-dependent manner after treatment with DXR or GSH-DXR, and caspase-3 activity correlated well with the ability to induce DNA fragmentation. When the cells were treated with either DXR or GSH-DXR for only 6 h, apoptotic DNA degradation and caspase-3 activation occurred 24 h after treatment. DNA fragmentation caused by these drugs was prevented completely by simultaneous treatment with the caspase-3 inhibitor, acetyl-Asp-Glu-Val-Asp-aldehyde (DEVD-CHO), at 10 microM. By contrast, DNA fragmentation was not prevented by the caspase-1 inhibitor, acetyl-Tyr-Val-Ala-Asp-aldehyde (YVAD-CHO), at the same concentration as DEVD-CHO, and caspase-1 was not activated at all by the treatment of AH66 cells with both DXR and GSH-DXR. These results demonstrate that DXR and GSH-DXR induce apoptotic DNA fragmentation via caspase-3 activation, but not via caspase-1 activation, and that GSH-DXR enhances the activation of caspase-3 approximately 100-fold more than DXR. Moreover, the findings suggested that an upstream apoptotic signal that can activate caspase-3 is induced within 6 h by treating AH66 cells with the drug.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10360648      PMCID: PMC2362273          DOI: 10.1038/sj.bjc.6690414

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  21 in total

1.  Induction of endonucleolytic DNA cleavage in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer drugs: a cautionary note.

Authors:  S H Kaufmann
Journal:  Cancer Res       Date:  1989-11-01       Impact factor: 12.701

2.  Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis.

Authors:  D W Nicholson; A Ali; N A Thornberry; J P Vaillancourt; C K Ding; M Gallant; Y Gareau; P R Griffin; M Labelle; Y A Lazebnik
Journal:  Nature       Date:  1995-07-06       Impact factor: 49.962

3.  Effects of cisplatin on the induction of apoptosis in proliferating hepatoma cells and nonproliferating immature thymocytes.

Authors:  D L Evans; C Dive
Journal:  Cancer Res       Date:  1993-05-01       Impact factor: 12.701

4.  Ich-1, an Ice/ced-3-related gene, encodes both positive and negative regulators of programmed cell death.

Authors:  L Wang; M Miura; L Bergeron; H Zhu; J Yuan
Journal:  Cell       Date:  1994-09-09       Impact factor: 41.582

5.  Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis.

Authors:  S H Kaufmann; S Desnoyers; Y Ottaviano; N E Davidson; G G Poirier
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

6.  Activation of intracellular proteases is an early event in TNF-induced apoptosis.

Authors:  C Voelkel-Johnson; A J Entingh; W S Wold; L R Gooding; S M Laster
Journal:  J Immunol       Date:  1995-02-15       Impact factor: 5.422

7.  CPP32, a novel human apoptotic protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian interleukin-1 beta-converting enzyme.

Authors:  T Fernandes-Alnemri; G Litwack; E S Alnemri
Journal:  J Biol Chem       Date:  1994-12-09       Impact factor: 5.157

8.  Aspartate-based inhibitor of interleukin-1 beta-converting enzyme prevents antitumor agent-induced apoptosis in human myeloid leukemia U937 cells.

Authors:  T Mashima; M Naito; S Kataoka; H Kawai; T Tsuruo
Journal:  Biochem Biophys Res Commun       Date:  1995-04-26       Impact factor: 3.575

9.  Glutathione-doxorubicin conjugate expresses potent cytotoxicity by suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells.

Authors:  T Asakura; K Ohkawa; N Takahashi; K Takada; T Inoue; S Yokoyama
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro.

Authors:  K Ohkawa; T Hatano; Y Tsukada; M Matsuda
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

View more
  6 in total

Review 1.  Delivery of intracellular-acting biologics in pro-apoptotic therapies.

Authors:  Hongmei Li; Chris E Nelson; Brian C Evans; Craig L Duvall
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

2.  Impact of mitochondrial telomerase over-expression on drug resistance of hepatocellular carcinoma.

Authors:  Jing Yan; Yuan Zhou; Daixing Chen; Lili Li; Xin Yang; Yang You; Xianlong Ling
Journal:  Am J Transl Res       Date:  2015-01-15       Impact factor: 4.060

3.  Study of apoptosis in human liver cancers.

Authors:  Chang-Min Shan; Juan Li
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

4.  Glutathione administration reduces mitochondrial damage and shifts cell death from necrosis to apoptosis in ageing diabetic mice hearts during exercise.

Authors:  S Golbidi; A Botta; S Gottfred; A Nusrat; I Laher; S Ghosh
Journal:  Br J Pharmacol       Date:  2014-12       Impact factor: 8.739

5.  The caspase pathway in noise-induced apoptosis of the chinchilla cochlea.

Authors:  Thomas M Nicotera; Bo Hua Hu; Donald Henderson
Journal:  J Assoc Res Otolaryngol       Date:  2003-10-13

6.  Upregulation of apoptotic protease activating factor-1 expression correlates with anti-tumor effect of taxane drug.

Authors:  Meysam Bakhshoudeh; Kayhan Mehdizadeh; Saman Hosseinkhani; Farangis Ataei
Journal:  Med Oncol       Date:  2021-06-28       Impact factor: 3.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.